Provided by Tiger Trade Technology Pte. Ltd.

Pacira Pharmaceuticals

25.05
-0.1600-0.63%
Post-market: 25.170.1200+0.48%19:32 EDT
Volume:560.25K
Turnover:14.08M
Market Cap:998.54M
PE:71.21
High:25.71
Open:25.37
Low:24.83
Close:25.21
52wk High:27.66
52wk Low:18.80
Shares:39.86M
Float Shares:36.37M
Volume Ratio:1.02
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3518
EPS(LYR):0.1578
ROE:2.05%
ROA:1.48%
PB:1.49
PE(LYR):158.71

Loading ...

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Pacira Pharmaceuticals (PCRX)

TIPRANKS
·
11 hours ago

Pacira Grants Stock Options for 3,600 Shares, RSUs for 4,200 Shares to New Hires Under Inducement Plan

Reuters
·
Yesterday

Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize Exparel® in the European Union and United Kingdom

THOMSON REUTERS
·
Yesterday

Pacira Biosciences, - to Receive Undisclosed Upfront Payment, Supply Price, and Royalties from Molteni

THOMSON REUTERS
·
Yesterday

Pacira Biosciences, - Molteni to Launch Exparel in Italy, Germany, Austria, Poland; First Sale Expected in 2027

THOMSON REUTERS
·
Yesterday

Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom

GlobeNewswire
·
Yesterday

Oppenheimer Initiates Pacira Biosciences at Outperform With $32 Price Target

MT Newswires Live
·
Sep 23

Pacira BioSciences Price Target Announced at $32.00/Share by Oppenheimer

Dow Jones
·
Sep 23

Pacira BioSciences Price Target Announced at $28.00/Share by Leerink Partners

Dow Jones
·
Sep 09

Pacira Grants Inducement Equity Awards to New Hires, Including Options Priced at $26.58 Per Share

Reuters
·
Sep 09

Pacira Biosciences Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 09

Leerink Partners Initiates Coverage on Pacira Biosciences With Market Perform Rating, $28 Price Target

MT Newswires Live
·
Sep 09

Pacira initiated with a Market Perform at Leerink

TIPRANKS
·
Sep 09

Pacira BioSciences CMO Jonathan Slonin Sells 3,040 Shares for $70,619.20

Reuters
·
Aug 19

Pacira Biosciences, Inc. : Truist Securities Reinstates Coverage with Buy Rating; Price Target $30

THOMSON REUTERS
·
Aug 17

Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data

Simply Wall St.
·
Aug 10

Pacira Grants Inducement Equity Awards to New Hires, Including Options Priced at $27.62/share

Reuters
·
Aug 07

Press Release: Pacira BioSciences Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dow Jones
·
Aug 07

Pacira Publishes Positive Two-Year Phase 1 Data for PCRX-201 Gene Therapy in Knee Osteoarthritis

Reuters
·
Aug 06

Pacira BioSciences is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Aug 06